Vancomycin Area Under the Curve Dosing and Monitoring at an Academic Medical Center: Transition Strategies and Lessons Learned

Eric R. Gregory; Donna R. Burgess; Sarah E. Cotner; Jeremy D. VanHoose; Alexander H. Flannery; Brian Gardner; Elizabeth B. Autry; Derek W. Forster; David S. Burgess; Katie L. Wallace

doi:10.1177/0897190019834369

Vancomycin Area Under the Curve Dosing and Monitoring at an Academic Medical Center: Transition Strategies and Lessons Learned

Eric R. Gregory, Donna R. Burgess, Sarah E. Cotner, Jeremy D. VanHoose, Alexander H. Flannery, Brian Gardner, Elizabeth B. Autry, Derek W. Forster, David S. Burgess, Katie L. Wallace

Pharmacy Practice and Science

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Due to the inconsistent correlation of vancomycin trough concentrations with 24-hour area under the curve (AUC) and a desire to reduce rates of vancomycin-associated acute kidney injury, an institutional guideline was implemented by the Antimicrobial Stewardship Team in September 2017 to monitor vancomycin using AUC. Three stages were utilized to organize the process: preparation, implementation, and evaluation. The preparation stage was used to present literature to key stakeholders, and pharmacy meetings focused on the development of a dosing and monitoring guideline. Along with institution-wide education, the implementation stage included information technology development and support. The evaluation stage was comprised of quality improvement and clinical research. Future plans include dissemination of the results and analyses. Numerous lessons were learned due to barriers experienced during the process, but the transition was successful.

Original language	English
Pages (from-to)	774-778
Number of pages	5
Journal	Journal of Pharmacy Practice
Volume	33
Issue number	6
DOIs	https://doi.org/10.1177/0897190019834369
State	Published - Dec 2020

Bibliographical note

Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The project described was supported by the NIH National Center for Advancing Translational Sciences through grant number UL1TR001998. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Funding Information:
The authors acknowledge the following individuals of the pharmacy work group at the University of Kentucky HealthCare who supported the implementation of the new therapeutic drug monitoring: Aaron Cook, PharmD, BCCP, BCPS, Ryan Crass, PharmD (Dr. Crass was a pharmacy resident at UK HealthCare during the preparation stage of this practice change and is currently a Clinical Translational Sciences Fellow at the University of Michigan College of Pharmacy), Krutika Mediwala, PharmD, BCPS (Dr. Mediwala was a pharmacy resident at UK HealthCare during the preparation stage of this practice change and is currently an Infectious Diseases/Antimicrobial Stewardship Clinical Pharmacist at MUSC Health), and Dwayne Pierce, PharmD, BCPS. The authors would also like to thank the Infectious Diseases physician faculty for their support and involvement in this process implementation. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The project described was supported by the NIH National Center for Advancing Translational Sciences through grant number UL1TR001998. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Publisher Copyright:
© The Author(s) 2019.

Keywords

acute kidney injury
area under the curve
therapeutic drug monitoring
vancomycin

ASJC Scopus subject areas

Pharmacy
Pharmacology (medical)

Access to Document

10.1177/0897190019834369

Cite this

Gregory, E. R., Burgess, D. R., Cotner, S. E., VanHoose, J. D., Flannery, A. H., Gardner, B., Autry, E. B., Forster, D. W., Burgess, D. S., & Wallace, K. L. (2020). Vancomycin Area Under the Curve Dosing and Monitoring at an Academic Medical Center: Transition Strategies and Lessons Learned. Journal of Pharmacy Practice, 33(6), 774-778. https://doi.org/10.1177/0897190019834369

@article{6c9449f37e5f4f2db0a54d5327780400,

title = "Vancomycin Area Under the Curve Dosing and Monitoring at an Academic Medical Center: Transition Strategies and Lessons Learned",

abstract = "Due to the inconsistent correlation of vancomycin trough concentrations with 24-hour area under the curve (AUC) and a desire to reduce rates of vancomycin-associated acute kidney injury, an institutional guideline was implemented by the Antimicrobial Stewardship Team in September 2017 to monitor vancomycin using AUC. Three stages were utilized to organize the process: preparation, implementation, and evaluation. The preparation stage was used to present literature to key stakeholders, and pharmacy meetings focused on the development of a dosing and monitoring guideline. Along with institution-wide education, the implementation stage included information technology development and support. The evaluation stage was comprised of quality improvement and clinical research. Future plans include dissemination of the results and analyses. Numerous lessons were learned due to barriers experienced during the process, but the transition was successful.",

keywords = "acute kidney injury, area under the curve, therapeutic drug monitoring, vancomycin",

author = "Gregory, {Eric R.} and Burgess, {Donna R.} and Cotner, {Sarah E.} and VanHoose, {Jeremy D.} and Flannery, {Alexander H.} and Brian Gardner and Autry, {Elizabeth B.} and Forster, {Derek W.} and Burgess, {David S.} and Wallace, {Katie L.}",

note = "Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The project described was supported by the NIH National Center for Advancing Translational Sciences through grant number UL1TR001998. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Funding Information: The authors acknowledge the following individuals of the pharmacy work group at the University of Kentucky HealthCare who supported the implementation of the new therapeutic drug monitoring: Aaron Cook, PharmD, BCCP, BCPS, Ryan Crass, PharmD (Dr. Crass was a pharmacy resident at UK HealthCare during the preparation stage of this practice change and is currently a Clinical Translational Sciences Fellow at the University of Michigan College of Pharmacy), Krutika Mediwala, PharmD, BCPS (Dr. Mediwala was a pharmacy resident at UK HealthCare during the preparation stage of this practice change and is currently an Infectious Diseases/Antimicrobial Stewardship Clinical Pharmacist at MUSC Health), and Dwayne Pierce, PharmD, BCPS. The authors would also like to thank the Infectious Diseases physician faculty for their support and involvement in this process implementation. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The project described was supported by the NIH National Center for Advancing Translational Sciences through grant number UL1TR001998. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Publisher Copyright: {\textcopyright} The Author(s) 2019.",

year = "2020",

month = dec,

doi = "10.1177/0897190019834369",

language = "English",

volume = "33",

pages = "774--778",

number = "6",

}

TY - JOUR

T1 - Vancomycin Area Under the Curve Dosing and Monitoring at an Academic Medical Center

T2 - Transition Strategies and Lessons Learned

AU - Gregory, Eric R.

AU - Burgess, Donna R.

AU - Cotner, Sarah E.

AU - VanHoose, Jeremy D.

AU - Flannery, Alexander H.

AU - Gardner, Brian

AU - Autry, Elizabeth B.

AU - Forster, Derek W.

AU - Burgess, David S.

AU - Wallace, Katie L.

N1 - Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The project described was supported by the NIH National Center for Advancing Translational Sciences through grant number UL1TR001998. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Funding Information: The authors acknowledge the following individuals of the pharmacy work group at the University of Kentucky HealthCare who supported the implementation of the new therapeutic drug monitoring: Aaron Cook, PharmD, BCCP, BCPS, Ryan Crass, PharmD (Dr. Crass was a pharmacy resident at UK HealthCare during the preparation stage of this practice change and is currently a Clinical Translational Sciences Fellow at the University of Michigan College of Pharmacy), Krutika Mediwala, PharmD, BCPS (Dr. Mediwala was a pharmacy resident at UK HealthCare during the preparation stage of this practice change and is currently an Infectious Diseases/Antimicrobial Stewardship Clinical Pharmacist at MUSC Health), and Dwayne Pierce, PharmD, BCPS. The authors would also like to thank the Infectious Diseases physician faculty for their support and involvement in this process implementation. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The project described was supported by the NIH National Center for Advancing Translational Sciences through grant number UL1TR001998. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Publisher Copyright: © The Author(s) 2019.

PY - 2020/12

Y1 - 2020/12

N2 - Due to the inconsistent correlation of vancomycin trough concentrations with 24-hour area under the curve (AUC) and a desire to reduce rates of vancomycin-associated acute kidney injury, an institutional guideline was implemented by the Antimicrobial Stewardship Team in September 2017 to monitor vancomycin using AUC. Three stages were utilized to organize the process: preparation, implementation, and evaluation. The preparation stage was used to present literature to key stakeholders, and pharmacy meetings focused on the development of a dosing and monitoring guideline. Along with institution-wide education, the implementation stage included information technology development and support. The evaluation stage was comprised of quality improvement and clinical research. Future plans include dissemination of the results and analyses. Numerous lessons were learned due to barriers experienced during the process, but the transition was successful.

AB - Due to the inconsistent correlation of vancomycin trough concentrations with 24-hour area under the curve (AUC) and a desire to reduce rates of vancomycin-associated acute kidney injury, an institutional guideline was implemented by the Antimicrobial Stewardship Team in September 2017 to monitor vancomycin using AUC. Three stages were utilized to organize the process: preparation, implementation, and evaluation. The preparation stage was used to present literature to key stakeholders, and pharmacy meetings focused on the development of a dosing and monitoring guideline. Along with institution-wide education, the implementation stage included information technology development and support. The evaluation stage was comprised of quality improvement and clinical research. Future plans include dissemination of the results and analyses. Numerous lessons were learned due to barriers experienced during the process, but the transition was successful.

KW - acute kidney injury

KW - area under the curve

KW - therapeutic drug monitoring

KW - vancomycin

UR - http://www.scopus.com/inward/record.url?scp=85062847182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062847182&partnerID=8YFLogxK

U2 - 10.1177/0897190019834369

DO - 10.1177/0897190019834369

M3 - Article

C2 - 30852937

AN - SCOPUS:85062847182

VL - 33

SP - 774

EP - 778

IS - 6

ER -

Vancomycin Area Under the Curve Dosing and Monitoring at an Academic Medical Center: Transition Strategies and Lessons Learned

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this